How is herpes simplex virus infection diagnosed and treated, including dosing for initial, recurrent, and suppressive therapy for oral and genital lesions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 27, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Diagnosis and Treatment of Herpes Simplex Virus Infection

Diagnostic Approach

Viral culture remains the most sensitive and specific method for diagnosing active HSV infection when genital ulcers are present, and type-specific molecular or virologic tests should be used to distinguish HSV-1 from HSV-2. 1

Active Lesion Testing

  • Obtain viral culture from vesicular or ulcerative lesions for definitive diagnosis 1
  • Type-specific molecular testing (PCR) can distinguish HSV-1 from HSV-2 and has prognostic importance for counseling about recurrence frequency 2
  • HSV-1 causes 5-30% of first-episode genital herpes cases but has much less frequent clinical recurrences than HSV-2 2

Serologic Testing

  • Type-specific serologic antibody tests can detect HSV-1 and HSV-2 antibodies when lesions are not present 1
  • Serology helps diagnose unrecognized infections but cannot determine timing of acquisition 3
  • Most genital herpes infections (over 90%) are unrecognized, making serologic testing valuable for identifying asymptomatic carriers 3

First Clinical Episode Treatment

For initial genital herpes, the CDC recommends acyclovir 400 mg orally three times daily for 7-10 days, with treatment extended if healing is incomplete after 10 days. 2

Standard Oral Regimens (7-10 days)

  • Acyclovir 400 mg orally three times daily 2
  • Acyclovir 200 mg orally five times daily 2
  • Valacyclovir 1 g orally twice daily 2
  • Famciclovir 250 mg orally three times daily 2

Important Considerations

  • Extend treatment beyond 10 days if healing is incomplete 2
  • Higher acyclovir dosages may be required for severe cases, particularly in immunocompromised patients 2
  • Topical acyclovir is substantially less effective than oral therapy and should not be used 2

Severe Disease Requiring Hospitalization

  • For severe disease, disseminated infection, or complications requiring hospitalization, administer acyclovir 5-10 mg/kg IV every 8 hours for 5-7 days or until clinical resolution 2

Recurrent Episode Treatment (Episodic Therapy)

Episodic therapy is most effective when started during the prodrome or within 1 day after onset of lesions; patients should be provided with medication to initiate treatment at the first sign of symptoms. 2

5-Day Episodic Regimens

  • Valacyclovir 500 mg orally twice daily 2
  • Acyclovir 800 mg orally twice daily 2
  • Acyclovir 400 mg orally three times daily 2
  • Acyclovir 200 mg orally five times daily 2
  • Famciclovir 125 mg orally twice daily 2

Prescribing Strategy

  • Provide patients with a prescription or medication supply to start at the first sign of prodrome or within 24 hours of lesion onset 2
  • Early initiation during prodrome maximizes benefit when viral replication peaks 2

Suppressive Therapy

Daily suppressive therapy should be offered to patients with ≥6 recurrences per year because it reduces recurrence frequency by ≥75%. 2

Daily Suppressive Regimens

  • Valacyclovir 1 g orally once daily (for ≥10 recurrences/year) 2
  • Valacyclovir 500 mg orally once daily (for <10 recurrences/year) 2
  • Acyclovir 400 mg orally twice daily 2, 4
  • Famciclovir 250 mg orally twice daily 2, 4

Duration and Reassessment

  • Safety and efficacy documented for acyclovir up to 6 years and for valacyclovir/famciclovir for 1 year 2
  • After 1 year of continuous suppressive therapy, discontinue temporarily to reassess recurrence frequency, as natural decline often occurs over time 2
  • Suppressive therapy controls 70-80% of symptomatic recurrences 4

Oral Herpes (Orolabial HSV)

Treatment of recurrent orolabial herpes is of questionable benefit because episodes tend to be mild and infrequent. 4

Clinical Context

  • Oral-labial HSV-1 recurs at a mean rate of only 0.12 per month, compared to 0.33 per month for genital HSV-2 5
  • The same antiviral regimens used for genital herpes can be applied to oral herpes when treatment is warranted 2
  • Episodic treatment may be considered for severe or frequent oral recurrences using the same 5-day regimens as genital herpes 2

Special Populations

Immunocompromised Patients

  • Higher doses of acyclovir (400 mg orally three to five times daily) are required until clinical resolution 2
  • If lesions persist despite acyclovir treatment, suspect viral resistance and consider foscarnet 40 mg/kg IV every 8 hours 2

HIV-Infected Patients

  • For recurrent genital herpes in HIV-infected patients, famciclovir 500 mg twice daily for 7 days is recommended 2
  • For suppressive therapy in HIV-infected patients, valacyclovir 500 mg orally twice daily (not once daily) is required 2

Pregnancy

  • Pregnant women with genital herpes should inform healthcare providers about the HSV infection 2
  • Antiviral prophylaxis from 36 weeks gestation until delivery is recommended for women with either a first or recurrent episode to lower term-time recurrences and cesarean-delivery rates 2
  • Women receiving acyclovir or valacyclovir during pregnancy should be reported to the manufacturer's pregnancy registry 2

Antiviral Resistance

Suspect acyclovir resistance if lesions fail to improve within 7-10 days of appropriate therapy; confirm with viral culture and susceptibility testing. 2

Management of Resistance

  • IV foscarnet 40 mg/kg every 8 hours is the treatment of choice for confirmed resistant HSV 2
  • Topical cidofovir, trifluridine, or imiquimod may be used for external lesions, requiring prolonged application (≈21-28 days) 2
  • Resistance is uncommon in immunocompetent hosts but more frequent in immunocompromised patients, especially those with HIV on long-term suppressive therapy 2

Patient Counseling Essentials

Natural History and Transmission

  • Patients should be counseled that genital herpes is a chronic, incurable infection with potential for lifelong recurrences 2
  • Asymptomatic viral shedding can occur even without visible lesions and even while on suppressive therapy, posing a transmission risk 2
  • HSV-2 leads to more frequent asymptomatic shedding than HSV-1, particularly during the first 12 months after infection 2

Timing of Infection

  • The first episode of visible genital lesions may indicate either recent or long-lasting infection; it is difficult to determine how or when a person became infected 3
  • In 80-90% of cases, genital herpes progresses subclinically after initial acquisition, with no visible symptoms at the time of transmission 3
  • The virus establishes latency in the sacral ganglia immediately after infection, and individuals can remain asymptomatic for months, years, or their entire lifetime 3
  • The appearance of symptoms does not prove recent sexual contact or infidelity 3

Prevention Strategies

  • Patients should abstain from all sexual activity when lesions or prodromal symptoms are present 2
  • All sexual partners should be informed about having genital herpes 2
  • Condoms should be used during all sexual exposures with new or uninfected partners, although condoms do not completely eliminate transmission risk 2
  • Suppressive therapy reduces transmission to uninfected partners in HIV-negative heterosexual couples but does not eliminate risk 2

Neonatal Transmission

  • Neonatal transmission risk is 25-44% with a primary episode at delivery versus ≈1% with recurrent infection 2
  • Patients should be counseled about the risk of neonatal infection, especially childbearing-aged women 2

Common Pitfalls to Avoid

  • Do not use valacyclovir 500 mg once daily in patients with ≥10 recurrences per year; it is less effective than higher-dose regimens 2
  • Do not delay initiation of episodic therapy; starting treatment during prodrome or within 1 day of lesion onset maximizes efficacy 2
  • Never assume that a first clinical episode indicates recent acquisition; the severity of the first episode does not correlate with timing of acquisition 3
  • Do not use topical acyclovir as it is substantially less effective than systemic oral antivirals 2

Renal Function Considerations

Assess renal function before starting and during antiviral therapy; adjust dosing frequency or total daily dose according to creatinine clearance to avoid toxicity. 2

  • Baseline renal function should be evaluated before starting therapy 6
  • For intravenous acyclovir, obtain renal function tests at therapy initiation and then once or twice weekly 2
  • Ensure adequate patient hydration during therapy to reduce risk of crystalluria and nephropathy 6

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

2
Guideline

Treatment Guidelines for Vaginal Herpes Simplex

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

3
Guideline

Genital Herpes Infection and Symptom Onset

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

6
Guideline

Management of Herpes Zoster

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is recurrent genital herpes in a sexually active adult with a history of previous genital herpes outbreaks?
What are the likely causes and recommended evaluation and treatment for recurrent blisters on the inner thigh of a 9‑year‑old girl?
What are the alternatives to Valtrex (Valacyclovir) for Herpes Simplex Virus (HSV)?
Is there a benefit to using 1 gram of valacyclovir (Valtrex) twice daily with topical valacyclovir (Valtrex) in sacral herpes, diagnosed late with prior use of topical corticosteroids?
Does a herpes outbreak after sexual activity necessarily mean the partner is infected with herpes?
What is the recommended post‑lung‑transplant care protocol for an adult recipient, including induction and maintenance immunosuppression, infection prophylaxis, laboratory and pulmonary function monitoring, surveillance bronchoscopy schedule, rejection treatment, chronic complication management, and lifestyle recommendations?
What is the appropriate treatment for herpangina in a child aged 3 months to 10 years?
What do you mean by saying that, despite my persistent insomnia, nausea, reflux, and tachycardia on 7.5 mg amitriptyline (even after a brief increase to 10 mg and use of sleep aids, acid‑suppressing drugs, anti‑emetics, and a short‑acting beta‑blocker), maintaining this low dose long‑term is an acceptable outcome?
How should an immunocompromised patient co-infected with Campylobacter and Shiga toxin-producing Escherichia coli be treated?
What additional treatment options are available for a 34‑year‑old man with rosacea who is already on low‑dose oral doxycycline and topical metronidazole gel?
Does azithromycin lower the seizure threshold?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question